Immunovant, Inc. (IMVT)
33.12
-0.05
(-0.15%)
USD |
NASDAQ |
Nov 19, 10:08
Immunovant Enterprise Value : 6.137B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 6.137B |
| November 17, 2026 | 6.145B |
| November 16, 2026 | 6.160B |
| November 13, 2026 | 6.346B |
| November 12, 2026 | 6.526B |
| November 11, 2026 | 6.937B |
| November 10, 2026 | 6.662B |
| November 09, 2026 | 6.546B |
| November 06, 2026 | 5.591B |
| November 05, 2026 | 5.148B |
| November 04, 2026 | 5.461B |
| November 03, 2026 | 5.283B |
| November 02, 2026 | 5.153B |
| October 30, 2026 | 5.310B |
| October 29, 2026 | 5.407B |
| October 28, 2026 | 5.361B |
| October 27, 2026 | 5.250B |
| October 26, 2026 | 5.103B |
| October 23, 2026 | 5.153B |
| October 22, 2026 | 5.295B |
| October 21, 2026 | 5.146B |
| October 20, 2026 | 5.190B |
| October 19, 2026 | 4.989B |
| October 16, 2026 | 4.805B |
| October 15, 2026 | 4.966B |
| Date | Value |
|---|---|
| October 14, 2026 | 5.047B |
| October 13, 2026 | 5.215B |
| October 12, 2026 | 5.374B |
| October 09, 2026 | 5.578B |
| October 08, 2026 | 5.535B |
| October 07, 2026 | 5.903B |
| October 06, 2026 | 5.918B |
| October 05, 2026 | 6.153B |
| October 02, 2026 | 6.230B |
| October 01, 2026 | 6.236B |
| September 30, 2026 | 6.263B |
| September 29, 2026 | 6.104B |
| September 28, 2026 | 6.110B |
| September 25, 2026 | 6.071B |
| September 24, 2026 | 6.215B |
| September 23, 2026 | 6.327B |
| September 22, 2026 | 6.894B |
| September 21, 2026 | 6.871B |
| September 18, 2026 | 6.824B |
| September 17, 2026 | 6.968B |
| September 16, 2026 | 6.706B |
| September 15, 2026 | 6.762B |
| September 14, 2026 | 6.970B |
| September 11, 2026 | 6.908B |
| September 10, 2026 | 7.061B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roivant Sciences Ltd. | 24.50B |
| Ionis Pharmaceuticals, Inc. | 4.847B |
| Vertex Pharmaceuticals, Inc. | 136.17B |
| Heron Therapeutics, Inc. | 161.18M |
| TG Therapeutics, Inc. | 10.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -97.25M |
| Total Expenses (Quarterly) | 97.25M |
| EPS Diluted (Quarterly) | -0.4705 |
| Earnings Yield | -7.70% |
| Normalized Earnings Yield | -7.703 |